Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL

被引:3
|
作者
Huang, Hua [1 ,2 ]
Liu, Zihao [1 ,2 ]
Ma, Yuan [1 ,2 ]
Shao, Yuan [1 ,2 ]
Yang, Zhen [1 ,2 ]
Duan, Dengyi [2 ,3 ]
Zhao, Yang [2 ,3 ]
Wen, Simeng [1 ,2 ]
Tian, Jing [1 ,2 ]
Liu, Yang [1 ,2 ]
Wang, Zeyuan [1 ,2 ]
Yue, Dan [2 ,4 ]
Wang, Yong [1 ,2 ]
机构
[1] Tianjin Med Univ, Hosp 2, Dept Urol, Tianjin 300211, Peoples R China
[2] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Tianjin, Peoples R China
[3] Tianjin Med Univ, Hosp 2, Dept Radiol, Tianjin, Peoples R China
[4] Tianjin Med Univ, Sch Med Lab, Tianjin 300070, Peoples R China
基金
中国国家自然科学基金;
关键词
ADC values; nomogram; PI-RADS; prostate cancer; prostate health index; HEALTH INDEX; CANCER DETECTION; ANTIGEN; DENSITY; PERFORMANCE; PERCENTAGE; DIAGNOSIS; IMPROVES; MPMRI; ZONE;
D O I
10.1002/pros.24658
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PurposeThe study aimed to investigate the diagnostic accuracy of prostate health index (PHI) and apparent diffusion coefficient (ADC) values in predicting prostate cancer (PCa) and construct a nomogram for the prediction of PCa and clinically significant PCa (CSPCa) in Prostate Imaging-Reporting and Data System (PI-RADS) three lesions cohort.MethodsThis study prospectively enrolled 301 patients who underwent multiparametric magnetic resonance (mpMRI) and were scheduled for prostate biopsy. The receiver operating characteristic curve (ROC) was performed to estimate the diagnostic accuracy of each predictor. Univariable and multivariable logistic regression analysis was conducted to ascertain hidden risk factors and constructed nomograms in PI-RADS three lesions cohort.ResultsIn the whole cohort, the area under the ROC curve (AUC) of PHI is relatively high, which is 0.779. As radiographic parameters, the AUC of PI-RADS and ADC values was 0.702 and 0.756, respectively. The utilization of PHI and ADC values either individually or in combination significantly improved the diagnostic accuracy of the basic model. In PI-RADS three lesions cohort, the AUC for PCa was 0.817 in the training cohort and 0.904 in the validation cohort. The AUC for CSPCa was 0.856 in the training cohort and 0.871 in the validation cohort. When applying the nomogram for predicting PCa, 50.0% of biopsies could be saved, supplemented by 6.9% of CSPCa being missed.ConclusionPHI and ADC values can be used as predictors of CSPCa. The nomogram included PHI, ADC values and other clinical predictors demonstrated an enhanced capability in detecting PCa and CSPCa within PI-RADS three lesions cohort.
引用
收藏
页码:376 / 388
页数:13
相关论文
共 36 条
  • [1] PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4-10 ng/ml
    Wen, Jing
    Liu, Wei
    Shen, Xiaocui
    Hu, Wei
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [2] The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20ng/mL
    Wang, Zhi-bing
    Wei, Chao-gang
    Zhang, Yue-yue
    Pan, Peng
    Dai, Guang-cheng
    Tu, Jian
    Shen, Jun-kang
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [3] Comparison in prostate cancer diagnosis with PSA 4-10 ng/mL: radiomics-based model VS. PI-RADS v2.1
    Li, Chunxing
    Jin, Zhicheng
    Wei, Chaogang
    Dai, Guangcheng
    Tu, Jian
    Shen, Junkang
    BMC UROLOGY, 2024, 24 (01):
  • [4] Utility of Prostate Health Index Density for Biopsy Strategy in Biopsy-Naïve Patients With PI-RADS v2.1 Category 3 Lesions
    Kim, Min Je
    Park, Jung Jae
    Kang, Kyung A.
    Park, Sung Yoon
    Kim, Chan Kyo
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2024, 60 (04) : 1628 - 1636
  • [5] Development of novel nomograms for predicting prostate cancer in biopsy-naive patients with PSA < 10 ng/ml and PI-RADS ≤ 3 lesions
    Chai, Jia-gui
    Li, Yu-hang
    Ke, Chang-xing
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [6] Development and validation of a novel nomogram to avoid unnecessary biopsy in patients with PI-RADS category ≥ 4 lesions and PSA ≤ 20 ng/ml
    Zeng, Hong
    Chen, Yuntian
    Zhao, Jinge
    Dai, Jindong
    Xie, Yandong
    Wang, Minghao
    Wang, Qian
    Xu, Nanwei
    Chen, Junru
    Sun, Guangxi
    Zeng, Hao
    Shen, Pengfei
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [7] The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP)
    Liu, Jiazhou
    Pan, Shihang
    Dong, Liang
    Wu, Guangyu
    Wang, Jiayi
    Wang, Yan
    Qian, Hongyang
    Dong, Baijun
    Pan, Jiahua
    Zhu, Yinjie
    Xue, Wei
    CURRENT ONCOLOGY, 2022, 29 (09) : 6373 - 6382
  • [8] Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer
    Wei, Xiaoting
    Xu, Jianmin
    Zhong, Shuyuan
    Zou, Jinsen
    Cheng, Zhiqiang
    Ding, Zhiguang
    Zhou, Xuhui
    ABDOMINAL RADIOLOGY, 2022, 47 (10) : 3574 - 3582
  • [9] A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL
    Liu, Feifan
    Wang, Jianyu
    Song, Yufeng
    Wu, Fei
    Wu, Haihu
    Lyu, Jiaju
    Ning, Hao
    FUTURE ONCOLOGY, 2025, 21 (04) : 463 - 471
  • [10] Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naive patients with PSA PI-RADS v2.1=3 lesions
    Hu, Can
    Sun, Jiale
    Xu, Zhenyu
    Zhang, Zhiyu
    Zhou, Qi
    Xu, Jiangnan
    Chen, Hao
    Wang, Chao
    Ouyang, Jun
    CANCER MEDICINE, 2023, 12 (03): : 2560 - 2571